[New drugs; daptomycin].
Being a cyclic lipopeptide, daptomycin belongs to a new class of antibiotics. It acts by forming a pore in the bacterial membrane thus causing leakage of potassium and subsequent depolarization and arrest of cell function. Daptomycin has a bactericidal action on Gram-positive bacteria and is registered for the treatment of adults with complicated skin and soft tissue infections caused by Gram-positive microorganisms. There is limited experience with treatment of Staphylococcus aureus bacteraemia. Its main adverse effects include gastrointestinal symptoms, skin reactions at the site of infusion, and raised serum creatine kinase.
van Bronswijk
H
H
Leids Universitair Medisch Centrum, Albinusdreef 2, 2333 ZA Leiden.
Dubois
E A
EA
van Dissel
J T
JT
Cohen
A F
AF
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood; D017576:Daptomycin / Q000009:adverse effects / Q000627:therapeutic use*; D005076:Exanthema / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D018461:Soft Tissue Infections / Q000188:drug therapy; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D003402:Creatine Kinase; D017576:Daptomycin